BIVI Stock Summary and Trading Ideas (Biovie | NASDAQ:BIVI)

BioVie Inc is a clinical-stage company developing drug therapies for the treatment of neurological and neurodegenerative disorders and liver disease. Its therapeutic areas include Alzheimer's, Parkinson's, Long COVID, Ascites, Longevity, and Epigenetics. In liver disease, its investigational drug candidate BIV201 (continuous infusion terlipressin) was granted FDA Fast Track status and FDA Orphan Drug designation for ascites due to all etiologies except cancer. BIV201 is being evaluated as a treatment option for patients suffering from life-threatening complications of liver cirrhosis and ascites due to hepatitis, nonalcoholic steatohepatitis, and alcoholism.

Biovie trades on the NASDAQ stock market under the symbol BIVI.

As of September 15, 2026, BIVI stock price declined to $1.75 with 837,010 million shares trading.

BIVI has a beta of -0.03, meaning it tends to be less sensitive to market movements. BIVI has a correlation of 0.00 to the broad based SPY ETF.

BIVI has a market cap of $14.79 million. This is considered a Sub-Micro Cap stock.

In the last 3 years, BIVI traded as high as $582.00 and as low as $.82.

The top ETF exchange traded funds that BIVI belongs to (by Net Assets): VXF.

BIVI has underperformed the market in the last year with a price return of -6.4% while the SPY ETF gained +16.4%. However, in the short term, BIVI had mixed performance relative to the market. It has outperformed in the last 3 months, returning +7.4% vs +2.4% return in SPY. But in the last 2 weeks, BIVI shares have been beat by the market, returning -23.2% compared to an SPY return of -1.3%.

BIVI support price is $1.84 and resistance is $2.26 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that BIVI shares will trade within this expected range on the day.